Singapore, Dec 08, 2011: China Health Resource, through its wholly owned subsidiary Suining Yinfa DAR Industrial Co, Ltd, the leader in GAP standard for Dahurian Angelica Root (DAR) in China under the registered Trademark Chuan Baizhi, has announced completion of key scientific research project in collaboration with Chengdu Chinese Traditional Medicine & Science University and the Sichuan Chinese Medicine Research Institute.
This research addresses innovative products in the areas of cough, diabetes, headaches, and chronic fatigue OTC and TCM pharmaceuticals. "We expect to announce some of the products addressed by this research regarding clinical trials and other commercial phases of development next," said Jiayin Wang, Chairman and CEO of CHRI.
Traditional Chinese medicine (TCM) pharmaceutical products, along with western pharmaceuticals, are essential to the central healthcare system in China. The industry has been and is expected to continue growing significantly. In recent years in western countries such as the U.S., awareness of the benefits of TCM products has become increasingly attractive.
"This research is key for the company's growth strategy as we become a more vertically integrated company in the near future. It allows us to maintain a strong competitive edge by managing the rare supply of pharmaceutical grade ingredients and it provides management direction for the effective deployment of our capital and resources in a manner that brings short and longer terms investment results," said Jiayin Wang, Chairman and CEO of CHRI. "The TCM pharmaceutical industry is highly fragmented especially in China and standards are needed to safeguard quality. Our early investment and major commitment in GAP standard DAR has resulted in a successful project with scientific discoveries which will increase our business significantly. We at CHRI are committed to establishing GAP standards to major TCM herbs for pharmaceutical use. CHRI is dedicated to this mission," added Mr. Wang.
The research project, which was formally started in April 2008, covered research related to DAR, Frictillaria, Berberine and other TCM herbs considered by company and industry experts to address major healthcare problems. The research included studies such as "Study of Primary Processing of Angelica Dahurian", "Establishment of Evaluation System for Angelica Dahurian Quality", "Study on Obtaining Effective Ingredients in Angelica Dahurian", "Development of New Headache Medicine in Tablets", "Research and Development of Angelica Dahurian (DAR) for Heath Care and Related Products" and others. These studies use DAR as a key ingredient in combination with other natural herbs. DAR is known for its properties to treat pain, swelling and pustule.
The research was supported by government grants and the intellectual property and commercial rights belongs to the company. The project incurred total expense of US$ 5.8 million (37.5 million RMB).
"We are very excited at the completion of this research project and thankful to our partners Chengdu TCM University and the Medicine Institute for their full cooperation. The level of scientific expertise in the TCM field was shown to be of the highest caliber and the results speak for themselves. This research will result in enhancing many of our existing products and more importantly provide the company with new proprietary products that can address health related ailments in more effective ways than at present adding to our competitive edge in the market," said Jiayin Wang, Chairman and CEO of CHRI.